TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Am J Hematol
; 96(8): E306-E310, 2021 08 01.
Article
in En
| MEDLINE
| ID: mdl-33989438
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Lymphocytic, Chronic, B-Cell
/
Tumor Suppressor Protein p53
Type of study:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Am J Hematol
Year:
2021
Document type:
Article
Affiliation country:
Italia
Country of publication:
Estados Unidos